10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2011 | |||
STATEMENTS OF OPERATIONS | |||
Period Ending Dec 31, 2011 10-K (Filed: Feb 21, 2012) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | |
| Revenues | |||
| Sanofi collaboration revenue | $ 326,609 | 311,332 | 247,140 |
| Other collaboration revenue | 43,072 | 75,393 | 67,317 |
| Net product sales | 44,686 | 25,254 | 18,364 |
| Technology licensing | 24,858 | 40,150 | 40,013 |
| Contract research and other | 6,599 | 6,945 | 6,434 |
| Total revenues | 445,824 | 459,074 | 379,268 |
| Expenses | |||
| Research and development | 529,506 | 489,252 | 398,762 |
| Selling, general, and admistrative | 117,261 | 65,201 | 52,923 |
| Cost of goods sold | 4,216 | 2,093 | 1,686 |
| Total expenses | 650,983 | 556,546 | 453,371 |
| Loss from operations | (205,159) | (97,472) | (74,103) |
| Other income (expense) | |||
| Investment income | 3,549 | 2,122 | 4,488 |
| Interest expense | (21,282) | (9,118) | (2,337) |
| Total other income (expense) | (17,733) | (6,996) | 2,151 |
| Net loss before income tax benefit | (222,892) | (104,468) | (71,952) |
| Income tax benefit | (1,132) | 0 | (4,122) |
| Net loss | (221,760) | (104,468) | (67,830) |
| Net loss per share, basic and diluted (in dollars per share) | (2.45) | (1.26) | (0.85) |
| Weighted average shares outstanding, basic and diluted (in shares) | 90,610 | 82,926 | 79,782 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2011 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |